This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
PICO
Question: Among patients with juvenile idiopathic arthritis, is the MMR booster immunogenic and does it affect their disease activity?
Question type: Prognosis
Study design: Randomized, open-label clinical equivalence trial
Investigators from 5 Dutch medical centers conducted a randomized open-label clinical trial to evaluate the immunogenicity and safety of the measles-mumps-rubella (MMR) booster vaccination in children with juvenile idiopathic arthritis (JIA) who had previously received their primary MMR vaccination. The study was conducted in patients 4 to 9 years old to allow patients in the nonvaccinated arm to receive their MMR booster on the normal schedule (age 9–10 years in Netherlands).
Patients who were on a biologic treatment for JIA (ie, etanercept, anakinra) had this treatment held for 5 half-lives before receiving the booster, and for an additional 3 to 7 …
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
Purchase access
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.